Semaglutide
Overview
Semaglutide is a long-acting GLP-1 receptor agonist and a synthetic analogue of human GLP-1, sharing about 94% sequence homology with native GLP-1. It is used clinically for type 2 diabetes and, in specific formulations and indications, for chronic weight management.
Semaglutide activates GLP-1 receptors in multiple tissues, influencing glucose regulation, appetite, caloric intake and gastric emptying.
- GLP-1 receptor signaling
- Glucose homeostasis
- Appetite and caloric intake
- Metabolic and endocrine signaling
Mechanism of Action
Semaglutide activates GLP-1 receptors in multiple tissues. Its main metabolic effects include increased glucose-dependent insulin secretion, decreased glucose-dependent glucagon secretion, reduced appetite and caloric intake, and delayed gastric emptying, particularly after meals. Reduction in body weight is predominantly associated with reduced energy intake. Its long duration is partly explained by albumin binding, which reduces renal clearance, together with structural modifications that protect it from degradation by DPP-4.
Studies involving semaglutide have examined receptor activity and downstream metabolic signaling associated with glucose homeostasis and energy balance.
Receptor Activity
Semaglutide is an agonist of the GLP-1 receptor. Activation of GLP-1R produces intracellular signaling associated with glucose-dependent insulin secretion and glucagon regulation.
GLP-1 receptors are present in brain regions involved in regulation of food intake. Activation of these pathways contributes to reduced appetite and caloric intake.
Metabolic Research
Research has investigated semaglutide in relation to glycemic control and HbA1c, fasting and postprandial glucose, visceral adipose tissue, lipid metabolism, appetite and satiety, and several cardiometabolic parameters. A 2025 review reported reductions in total and visceral fat while describing relative preservation of lean mass during treatment. More recent systems-level research is investigating effects on inflammatory pathways, lipid metabolism and extracellular-matrix signaling across different organs.
Research Context
Semaglutide is an established clinical drug rather than an experimental research peptide. Its GLP-1 receptor mechanism, glucose-lowering effects and effects on appetite have been extensively studied in humans. Current research is moving beyond diabetes and weight management toward understanding its cardiovascular, renal, metabolic and multisystem effects.
Semaglutide is a long-acting GLP-1 receptor agonist that regulates glucose metabolism, appetite and energy intake. By activating GLP-1 receptors, it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and influences central appetite pathways. Research continues to investigate its broader metabolic, cardiovascular and systemic effects.